Four second-generation BCR-ABL inhibitors (dasatinib, nilotinib, bosutinib and ponatinib) were also tested alongside imatinib in the CML-T1 cell line and shown to synergize with MDM2 antagonism (Figure S4). Here, MDM2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.